Computer prediction of drug resistance mutations in proteins

Drug Discovery Today

Volumn 10, Issue 7, 2005, Pages 521-529

  Cao, Zhi Wei ^a   Han, Lian Yi ^a   Zheng, Chan Juan ^a   Ji, Zhi Lang ^b   Chen, Xin ^a   Lin, Hong Huang ^a   Chen, Yu Zong ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AGL 2043; AMPRENAVIR; ATAZANAVIR; CHLOROQUINE; CISPLATIN; CLARITHROMYCIN; D 64406; D 65476; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; FANSIDAR; FLUOROURACIL; GTP 14564; INDINAVIR; INTERFERON; ISONIAZID; K 252A; LAMIVUDINE; LOPINAVIR; MIDOSTAURIN; NELFINAVIR; NEVIRAPINE; PENICILLIN G; PROTEINASE; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; SB 203386; STAVUDINE; SU 5614; TENOFOVIR; U 89360 E; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTIFICIAL NEURAL NETWORK; CANCER; COMPUTER SYSTEM; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; GENOTYPE; INFECTION; MOLECULAR DYNAMICS; MOLECULAR MODEL; MONTE CARLO METHOD; PREDICTION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STATISTICAL ANALYSIS;

COMPUTER SIMULATION; COMPUTING METHODOLOGIES; DRUG RESISTANCE; MODELS, MOLECULAR; MUTATION; NEURAL NETWORKS (COMPUTER); PROTEIN CONFORMATION; PROTEINS;

EID: 17044404749     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03377-5     Document Type: Review

References (70)

1. Chaix-Couturier C., et al. HIV-1 drug resistance genotyping. A review of clinical and economic issues. Pharmacoeconomics. 18:2000;425-433
2. Liu H.H. Antibiotic resistance in bacteria. A current and future problem. Adv. Exp. Med. Biol. 455:1999;387-396
3. Lehne G., et al. Challenging drug resistance in cancer therapy-review of the First Nordic Conference on Chemoresistance in Cancer Treatment, October 9th and 10th, 1997. Acta Oncol. 37:(5):1998;431-439
4. Erickson J.W., Burt S.K. Structural mechanisms of HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 36:1996;545-571
5. Blanchard J.S. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu. Rev. Biochem. 65:1996;215-239
6. Borst P. Genetic mechanisms of drug resistance. A review. Acta Oncol. 30:1991;87-105
7. Remy S., et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann. Neurol. 53:2003;469-479
8. Schafer J.M., et al. A mechanism of drug resistance to tamoxifen in breast cancer. J. Steroid Biochem. Mol. Biol. 83:2002;75-83
9. Weber I.T., Harrison R.W. Molecular mechanics analysis of drug-resistant mutants of HIV protease. Protein Eng. 12:1999;469-474
10. Sussman F., et al. Solvation effects are responsible for the reduced inhibitor affinity of some HIV-1 PR mutants. Protein Sci. 6:1997;1024-1030
11. Rick S.W., et al. Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV-1 protease. Protein Sci. 7:1998;1750-1756
12. Piana S., et al. Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations. Protein Sci. 11:2002;2393-2402
13. Wang W., Kollman P.A. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc. Natl. Acad. Sci. U.S.A. 98:2001;14937-14942
14. Chen Y.Z., et al. Can an optimization/scoring procedure in ligand-protein docking be employed to probe drug-resistant mutations in proteins? J. Mol. Graph. Model. 19:2001;560-570
15. Shenderovich M.D., et al. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance. Protein Sci. 12:2003;1706-1718
16. Nair A.C., et al. Computational studies of the resistance patterns of mutant HIV-1 aspartic proteases towards ABT-538 (ritonavir) and design of new derivatives. J. Mol. Graph. Model. 21:2002;171-179
17. Stoffler D., et al. Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance. Proteins. 48:2002;63-74
18. Rhee S.Y., et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 31:2003;298-303
19. Zazzi M., et al. Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype. J. Antimicrob. Chemother. 53:2004;356-360
20. Wang D., Larder B. Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. J. Infect. Dis. 188:2003;653-660
21. Draghici S., Potter R.B. Predicting HIV drug resistance with neural networks. Bioinformatics. 19:2003;98-107
22. Beerenwinkel N., et al. Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res. 31:2003;3850-3855
23. Beerenwinkel N., et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8271-8276
24. Ala P.J., et al. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry. 36:1997;1573-1580
25. Rozwarski D.A., et al. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science. 279:1998;98-102
26. Avram S., et al. Comparative study of some energetic and steric parameters of the wild type and mutants HIV-1 protease: a way to explain the viral resistance. J. Cell. Mol. Med. 6:2002;251-260
27. Smith M.B., et al. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity. Protein Eng. 13:2000;413-421
28. Kuntz I.D. Structure-based strategies for drug design and discovery. Science. 257:1992;1078-1082
29. Blundell T.L. Structure-based drug design. Nature. 384:(Suppl. 6604):1996;23-26
30. Rarey M., et al. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 261:1996;470-489
31. Jones G., et al. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267:1997;727-748
32. Wang J., et al. Flexible ligand docking: a multistep strategy approach. Proteins. 36:1999;1-19
33. Charifson P.S., et al. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J. Med. Chem. 42:1999;5100-5109
34. Muegge I., Martin Y.C. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J. Med. Chem. 42:1999;791-804
35. Eisenberg D., McLachlan A.D. Solvation energy in protein folding and binding. Nature. 319:1986;199-203
36. Wang R., et al. SCORE: a new empirical method for estimating the bind affinity of a protein-ligand complex. J. Mol. Model. 4:1998;379-394
37. Chen X., et al. Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir. J Mol Model (Online). 10:2004;373-381
38. Kroeger Smith M.B., et al. Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: implications for the mechanism of polymerase action. Protein Eng. 10:1997;1379-1383
39. Arnold E., et al. Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. Drug Des Discov. 13:1996;29-47
40. Hu J.S., et al. A flexible approach of measuring mRNA expression levels of any genes using a universal oligonucleotide microarray. FASEB JOURNAL. 16:2002;. A543-A543
41. Puchhammer-Stockl E., et al. Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains. HIV Med. 3:2002;200-206
42. Thomson R., et al. Characterizing proteolytic cleavage site activity using bio-basis function neural networks. Bioinformatics. 19:2003;1741-1747
43. Berman H.M., et al. The Protein Data Bank. Nucleic Acids Res. 28:2000;235-242
44. van Doorn L.J., et al. Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob. Agents Chemother. 45:2001;1500-1504
45. Walter H., et al. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob. Agents Chemother. 46:2002;89-94
46. Victor T.C., et al. Prediction of drug resistance in M. tuberculosis: molecular mechanisms, tools, and applications. IUBMB Life. 53:2002;231-237
47. Talisuna A.O., et al. Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda. Trans. R. Soc. Trop. Med. Hyg. 97:2003;338-342
48. Cools J., et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 64:2004;6385-6389
49. Stefanelli P., et al. Prediction of decreased susceptibility to penicillin of Neisseria meningitidis strains by real-time PCR. J. Clin. Microbiol. 41:2003;4666-4670
50. Zavodszky M.I., et al. Modeling correlated main-chain motions in proteins for flexible molecular recognition. Proteins. 57:2004;243-261
51. Floriano W.B., et al. HierVLS hierarchical docking protocol for virtual ligand screening of large-molecule databases. J. Med. Chem. 47:2004;56-71
52. Liu Y., Beveridge D.L. Exploratory studies of ab initio protein structure prediction: multiple copy simulated annealing, AMBER energy functions, and a generalized born/solvent accessibility solvation model. Proteins. 46:2002;128-146
53. Burghardt T.P., et al. Cation-pi interaction in a folded polypeptide. Biopolymers. 63:2002;261-272
54. Cheung P.K., et al. 2004: which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev. 6:2004;107-116
55. Anderson T.J. Mapping drug resistance genes in Plasmodium falciparum by genome-wide association. Curr. Drug Targets Infect. Disord. 4:2004;65-78
56. Weinstein J.N., et al. An information-intensive approach to the molecular pharmacology of cancer. Science. 275:1997;343-349
57. Tamalet C., et al. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS. 17:2003;2383-2388
58. Yahi N., et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J. Clin. Microbiol. 37:1999;4099-4106
59. Russell Stuart, J. and Norvig, P. (2003) Artificial intelligence: a modern approach, Prentice Hall
60. Quinlan J.R. Induction of Decision Trees. Mach. Learn. 1:1986;81-106
61. Rutkowski L. Generalized regression neural networks in time-varying environment. IEEE Trans. Neural Netw. 15:2004;576-596
62. Wang Y.M., et al. Nonlinear estimation and modeling of fMRI data using spatio-temporal support vector regression. Inf Process Med Imaging. 18:2003;647-659
63. Cherkassky V., Ma Y. Practical selection of SVM parameters and noise estimation for SVM regression. Neural Netw. 17:2004;113-126
64. Sreevatsan S., et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob. Agents Chemother. 41:1997;1677-1681
65. Kiepiela P., et al. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuber. Lung Dis. 80:2000;47-56
66. Whelen A.C., et al. Direct genotypic detection of Mycobacterium tuberculosis rifampin resistance in clinical specimens by using single-tube heminested PCR. J. Clin. Microbiol. 33:1995;556-561
67. Williams D.L., et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:1998;1853-1857
68. Flueck T.P., et al. Correlation of in vivo-resistance to chloroquine and allelic polymorphisms in Plasmodium falciparum isolates from Uganda. Trop. Med. Int. Health. 5:2000;174-178
69. Nishiguchi S., et al. Method to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy. Hepatology. 33:2001;241-247
70. Blons H., et al. Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin. Cancer Res. 10:2004;2594-2599